

# Beslut vid Fru Berta Kamprads styrelsemöte 24 april 2019

## **Mattias Belting, FBKS-2019-29**

*Targeting the tumor microenvironment of solid tumors*

Anslag beviljat: 2019-2022

## **Åke Borg och Johan Vallon-Christersson, FBKS-2019-20**

*Bröstcancer - genomisk analys och deep learning för framtida diagnostik och prognostik*

Anslag beviljat: 2019-2022

## **Ana Bosch Campos, FBKS-2019-36**

*Resistance to endocrine treatment in estrogen receptor positive breast cancer. The role of systemic and local host factors*

Anslag beviljat: 2019-2022

## **Ana Carneiro, FBKS-2019-41**

*Cutaneous Malignant Melanoma: understanding resistance and improving response rates to immunotherapy*

Anslag beviljat: 2019-2020

## **Kristina Drott, FBKS-2019-14**

*BIO-MUSE: Towards clinically actionable biomarkers for patient stratification in mycosis fungoides and Sézary syndrome*

Anslag beviljat: 2019-2022

## **Pontus Eriksson, FBKS-2019-35**

*Single cell transcriptomic analysis of the normal urothelium and urothelial tumors*

Anslag beviljat: 2019-2020

## **Karin Fjordén, FBKS-2019-16**

*Exploring the future clinical applications of circulating tumor DNA in lymphoma - a national collaboration to standardize sample collection and analysis*

Anslag beviljat: 2019-2022

## **Adalsteinn Gunnlaugsson, FBKS-2019-22**

*Individualized treatment with PSMA-PET and PSA-response based treatment prediction during salvage radiotherapy of prostate cancer recurrence for improved outcome*

Anslag beviljat: 2019-2022

## **Ingrid Hedenfalk, FBKS-2019-28**

*Ovarian Cancer: Tumour Evolution, early detection and phenotype-targeted therapy*

Anslag beviljat: 2019-2022

**Mattias Höglund, FBKS-2019-3**

*Uroscan-Seq: Translation of molecular classification of urothelial carcinoma into clinical routines*

Anslag beviljat: 2019-2022

**Helena Jernström, FBKS-2019-13**

*Joint effects of genes, lifestyle, body constitution and tumor marker: exploring novel pathways to predict prognosis in different treatment groups of breast cancer patients - the BCBlood study*

Anslag beviljat: 2019-2022

**Göran Jönsson, FBKS-2019-17**

*Investigations of secondary Ig-deficiency in lymphoma patients, treated with rituximab (ISIDOR)*

Anslag beviljat: 2019-2022

**Göran B Jönsson, FBKS-2019-23**

*A molecular approach to understand response and resistance to immune checkpoint therapy in melanoma*

Anslag beviljat: 2019-2022

**Jenny-Maria Jönsson, FBKS-2019-43**

*Homologous recombination repair deficiency and prediction of PARP inhibition treatment effect in serous endometrial cancer*

Anslag beviljat: 2019-2020

**Anna F Karlsson, FBKS-2019-10**

*Comprehensive molecular characterization of clinically relevant subgroups of lung cancer patients*

Anslag beviljat: 2019-2020

**Anna-Maria Larsson, FBKS-2019-19**

*Circulating biomarkers to improve prognostication and treatment monitoring in metastatic breast cancer - with a translational focus on immune response and hypoxia*

Anslag beviljat: 2019-2020

**Michael Ljungberg, FBKS-2019-44**

*Dosimetry based Quantitative 3D Iterative Tomographic Image Reconstruction. Applications in Radionuclide Therapy of complex decay schemes, such as, 90-Yttrium, 177-Lu, 131-Iodine and 223-Radium*

Anslag beviljat: 2019-2022

**Niklas Loman, FBKS-2019-47**

*Nordic Trip - A translational randomized phase III study exploring the effect of the addition of Capecitabine to Carboplatin based preoperative chemotherapy in early triple negative breast cancer*

Anslag beviljat: 2019-2022

**Selamawit Mekuria FBKS-2019-6**

*Studies of HPV and cervical cancer in Ethiopia*

Anslag beviljat: 2019-2020

**Mef Nilbert, FBKS-2019-12**

*Multidisciplinary treatment conferences in cancer care; function, leadership and decision-making*

Anslag beviljat: 2019-2020

**Emma Niméus och Thomas Laurell, FBKS-2019-27**

*An integrative workflow for investigations of immune cell populations in triple negative breast cancer*

Anslag beviljat: 2019-2022

**Håkan Olsson, FBKS-2019-5**

*Genetic and environmental risk factors for common malignant tumours especially breast cancer, ovarian cancer and malignant melanoma*

Anslag beviljat: 2019-2022

**Lars E Olsson, FBKS-2019-11**

*MRI-only treatment planning of brain cancer to enable improved radiotherapy with less adverse reactions*

Anslag beviljat: 2019-2020

**Gudrun Oskarsdóttir, FBKS-2019-32**

*Surgical treatment for lung cancer - immunohistochemistry and mutational analysis on a population based, nationwide cohort.*

Anslag beviljat: 2019-2020

**Maria Planck, FBKS-2019-49**

*Blood and tumor based characterization of small cell lung cancer*

Anslag beviljat: 2019-2022

**Ann Rosendahl, FBKS-2019-48**

*OBELIA: The obesity breast cancer linkage investigation - promoting better health for women*

Anslag beviljat: 2019-2022

**Carlos Rovira, FBKS-2019-34**

*Somatic aberrations, convergent fusion genes and biomarkers in breast cancer*

Anslag beviljat: 2019-2020

**Tanja Stocks, FBKS-2019-1**

*Rökning och cancer i urinblåsa och prostata: Påverkar rökning risk och prognos, och spelar ärftlighet någon roll?*

Anslag beviljat: 2019-2020

**Yutaka Sugihara, FBKS-2019-26**

*Is clear cell sarcoma the same disease as melanoma?*

Anslag beviljat: 2019-2020

**Charlotte Welinder, FBKS-2019-37**

*Evaluation of new therapeutic and diagnostic antibodies against modified proteins associated with cancer*

Anslag beviljat: 2019-2020

**Oskar Vilhelmsson Timmermand, FBKS-2019-46**

*The development of prognostic and therapeutic tools identifying cancer initiating cells:*

*Targeting the luminal stem cell marker (LSCM) in recurrent cancer*

Anslag beviljat: 2019-2020